Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer medicines. They focus on cell cycle biology, specifically targeting the mechanisms that control cell growth and division. Their strategy is to create a diverse portfolio of novel drug candidates that address oncology and hematology indications, aiming to improve the lives of patients and their families. Cyclacel is a pioneer in the field, utilizing their expertise in cancer biology to research and develop medicines that combat the growing problem of resistance to anticancer therapeutics.

Cyclacel currently has two orally-available programs in clinical development: Fadraciclib, a cyclin-dependent kinase (CDK)-2 and-9 inhibitor, and Plogosertib, a polo-like kinase 1 (PLK1) inhibitor. The company is committed to scientific innovation, creativity, and integrity in its approach to biotechnology, with a strong focus on camaraderie and responsibility towards patients, healthcare professionals, and stockholders. Their leadership team has a proven track record of developing innovative medicines for oncology and hematology indications.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines that address the growing problem of drug resistance. They use insights in cancer biology to research and develop medicines that target various phases of cell cycle control, ultimately aiming to suppress mechanisms of resistance and reactivate the body’s own cell death mechanisms to destroy cancer cells.

Cyclacel Pharmaceuticals fosters a culture of mutual respect and shared values, motivated by the goal of developing innovative cancer therapies that are convenient for patients. They emphasize scientific innovation, creativity, and integrity, with a strong sense of responsibility toward patients, health professionals, society, and stockholders driving their work. This camaraderie and commitment to making a difference attracts individuals who share their core values and want to join a team determined to positively impact the lives of patients.

Cyclacel Pharmaceuticals is committed to fostering a diverse, equitable, and inclusive workplace. The company prioritizes creating an environment where everyone feels respected and valued, regardless of background or identity. This commitment is reflected in their equal opportunity employer statement and their emphasis on shared core values of scientific innovation, creativity, and integrity. Cyclacel values camaraderie and a strong sense of responsibility to patients, healthcare professionals, society, and stockholders, which forms the foundation for a workplace where all employees can contribute their unique perspectives and talents.